...

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor plus breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)

【24h】

Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor plus breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI)

机译：NRG肿瘤学的十年结果/ NSABP B-42：延长佐剂内分泌治疗的随机，双盲，安慰剂对照临床试验，延长佐剂内分泌治疗，含有激素受体加乳腺癌（BC）的绝经后妇女用芳香酶抑制剂（AI）完成了先前的佐剂治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献

1. Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor plus breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：NRG肿瘤学的十年结果/ NSABP B-42：延长佐剂内分泌治疗的随机，双盲，安慰剂对照临床试验，延长佐剂内分泌治疗，含有激素受体加乳腺癌（BC）的绝经后妇女用芳香酶抑制剂（AI）完成了先前的佐剂治疗
2. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 20, pg 88, 2019) [J] . Mamounas E. P., Bandos H., Lembersky B. C. The lancet oncology . 2019,第1期

机译：在绝经后乳腺癌中使用芳香酶抑制剂的治疗方法（NRG肿瘤学/ NSABP B-42）：随机，双盲，安慰剂控制，第3阶段试验（Vol 20，PG 88,2019）
3. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial [J] . Mamounas Eleftherios P., Bandos Hanna, Lembersky Barry C., The lancet oncology . 2019,第1期

机译：在绝经后乳腺癌中使用芳香酶抑制剂的使用后使用Letrozole（NRG肿瘤学/ NSABP B-42）：A随机，双盲，安慰剂控制，第3期试验
4. Musculoskeletal symptoms in women on aromatase inhibitors for adjuvant breast cancer therapy. [D] . Olufade, Temitope. 2012

机译：妇女在芳香酶抑制剂上的肌肉骨骼症状可用于辅助性乳腺癌治疗。
5. Interpreting breast international group (BIG) 1-98: a randomized double-blind phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer [O] . Meredith M Regan, Karen N Price, Anita Giobbie-Hurder, 2011

机译：国际乳腺癌解释组织（BIG）1-98：一项随机双盲III期试验比较来曲唑和他莫昔芬作为激素受体阳性的绝经后早期乳腺癌的辅助内分泌治疗方法
6. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer [O] . Regan, Meredith M., Price, Karen N., Giobbie-Hurder, Anita, 2017

机译：解释乳腺国际组织（BIG）1-98：一项随机，双盲，III期试验，比较来曲唑和他莫昔芬作为辅助内分泌治疗对绝经后激素受体阳性早期乳腺癌患者的影响

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号